$39 per month* $39 per month*
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Bionano Genomics’ Revenue by Region from Q1 2018 onwards, split between the Asia Pacific, EMEIA, and North America.
Bionano Genomics is a global pioneer in optical genome mapping technologies for genome analysis. where the company examines the structural variations of long segments of genomic DNA and other biomolecules The company provides proprietary nanochannel chips, an automated imaging instrument, integrated primary and secondary software, and application-specific reagents. Based on the Saphyr system, the company provides tools and services to scientists and clinicians conducting genetic research and patient testing. Through its owned subsidiary, Lineagen, Inc., the firm also provides diagnostic testing services for child patients suspected of having neurodevelopmental impairments.
Bionano Genomics’ generates its revenue from the following regions:
The following table sheds more light on each of the region and their contribution to the company’s overall top line.
|Regions||Q1 2020||Q1 2021||YOY Growth||Revenue Share in Q1 2021|
(All figures in thousands, except percentages)
Bionano Genomics’ Inc’s total revenue has been steadily increasing from $1,136 thousand in Q1 2020 to $3,168 thousand in Q1 2021, which shows a 178.87% increase year-over-year.
Bionano Genomics’ Inc revenue is further bifurcated into the following regions:
China, Japan, South Korea, Singapore, and Australia are all part of the Asia Pacific region.
This region contributed 2.62% of the total revenue in Q1 2021. Its revenue grew from $20 thousand in Q1 2020 to $83 thousand in Q1 2021, which shows a 315% increase. In 2020, this region’s revenue steadily increased from $20 thousand in Q1 2020 to $630thousand in Q1 2021.
EMEIA region includes Europe, Middle East, India, and Africa.
A majority of Bionano Genomics’ revenue comes from EMEIA, which contributed about 50.09% of total revenue in Q1 2021 amounting to $1,587 thousand. There was a 306.92% increase in revenue compared to the previous year where the revenue generated from this region was $390 thousand.
In the North America region, the company operates in the United States and Canada.
This region contributed 47.29% of the total revenue in Q1 2021. Its revenue grew from $726 thousand in Q1 2020 to $1,498 thousand in Q1 2021, which is a 106.34% increase.
For the fiscal years ended December 31, 2020, and 2019, the United States accounted for 42 % and 47 % revenue, respectively, while China accounted for 8 % and 7%.
Han Cao founded the Bionano Genomics’ in January 2003, and it is headquartered in San Diego, California, United States. Bionano Genomics’ traded on the NASDAQ under the symbol “BNGO”. In its initial public offering on September 21, 2018, its stock opened at $6.13. The company faces tough competition from Nabsys, PacBio, Genomic Vision, GenapSys, Oxford Nanopore, GnuBIO, LaserGen, OncoDNA, and QIAGEN.
Bionano Genomics’ had 147 employees as of December 31, 2020, with 72 workings in sales, sales support, and marketing, 38 in research and development, 24 in operations, and 13 in general and administrative. 126 of the 147 employees were based in the United States, with the remaining 21 working in countries other than the United States. Lineagen, Inc. has been acquired by the company to accelerate the clinical adoption of Saphyr for Digital Cytogenetics.
Did you like Bionano Genomics’ Revenue by Region statistic?
Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.
You can also get started for free.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.